Advertisement

CNS Drugs

, Volume 27, Issue 11, pp 913–920 | Cite as

Dexmedetomidine for the Treatment of Alcohol Withdrawal Syndrome: Rationale and Current Status of Research

  • Andrew J. MuzykEmail author
  • Suzanne Kerns
  • Scott Brudney
  • Jane P. Gagliardi
Review Article

Abstract

Dexmedetomidine is currently used in the US in the treatment of alcohol withdrawal syndrome (AWS) in the intensive care unit (ICU) setting, although data to support this practice are limited. Dexmedetomidine targets the noradrenergic system, an important but frequently overlooked secondary mechanism in the development of AWS, and, in doing so, may reduce the need for excessive benzodiazepine use which can increase the risk of γ-aminobutyric acid (GABA)-mediated deliriogenesis and respiratory depression. The purpose of this narrative review is to evaluate available literature reporting on the safety and efficacy of dexmedetomidine for AWS in the ICU setting. An English-language MEDLINE search (1966 to July 2013) was performed to identify articles evaluating the efficacy and safety of dexmedetomidine for AWS. Case series, case reports and controlled trials were evaluated for topic relevance and clinical applicability. Reference lists of articles retrieved through this search were reviewed to identify any relevant publications. Studies focusing on the safety and efficacy of dexmedetomidine for AWS in humans were selected. Studies were included if they were published as full articles; abstracts alone were not included in this review. Eight published case studies and case series were identified. Based on a limited body of evidence, dexmedetomidine shows promise as a potentially safe and possibly effective adjuvant treatment for AWS in the ICU. Prospective, well-controlled studies are needed to confirm the safety and efficacy of the use of dexmedetomidine in AWS.

Keywords

Intensive Care Unit Clonidine Locus Coeruleus Dexmedetomidine Alcohol Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Financial disclosure

No financial support was received for this publication. Drs. Kerns and Gagliardi have no sources of financial support relevant to this publication. Drs. Muzyk and Brudney are on the speaker’s bureau for Hospira (manufacturer of Precedex® brand of dexmedetomidine).

Additional disclosure

This article (in part or in whole) has not been previously presented or published.

References

  1. 1.
    McKeon A, Frye M, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2007;79:854–62.PubMedCrossRefGoogle Scholar
  2. 2.
    de Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. Chest. 2010;138:994–1003.PubMedCrossRefGoogle Scholar
  3. 3.
    Genther D, Gourin C. The effect of alcohol abuse and alcohol withdrawal on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122:1739–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Awissi D, Lebrun G, Coursin DB, Riker RR, Skrobik Y. Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med. 2013;39:16–30.PubMedCrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  6. 6.
    Monte R, Rabunal R, Casariego E. Risk factors for delirium tremens in patients with alcohol withdrawal syndrome in a hospital setting. Eur J Intern Med. 2009;20:690–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Stern TA. Alcohol-induced disorders. In: Stern TA, Rosenbaum JF, Fava M, editors. Massachusetts general hospital comprehensive clinical psychiatry, vol. 1. New York: Mosby/Elsevier; 2008. p. 1059–60.Google Scholar
  8. 8.
    McKeon A, Frye M, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2008;79:854–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Hall W, Zador D. The alcohol withdrawal syndrome. Lancet. 1997;349:1897–900.PubMedCrossRefGoogle Scholar
  10. 10.
    Borg S, Kvande H, Sedvall G. Central norepinephrine metabolism during alcohol intoxication in addicts and health volunteers. Science. 1981;213:1137.CrossRefGoogle Scholar
  11. 11.
    Linnoila M, Mefford I, Nutt D, Adinoff B. NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med. 1987;107:879.CrossRefGoogle Scholar
  12. 12.
    Mayo-Smith M, Beecher L, Fischer T, Gorelick D, Guillaume J, Jara G, Kasser C, Melbourne J. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004;164:1405–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayo-Smith. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management. JAMA. 1997;278(2):144–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Manasco A, Chang S, Larriviere J, Hamm LL, Glass M. Alcohol withdrawal. South Med J. 2012;105(11):607–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011;(6):CD008537.Google Scholar
  16. 16.
    Rayner SG, Weinert CR, Peng H, Jepsen S, Broccard AF. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(12):1–6.Google Scholar
  17. 17.
    Tolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med. 2012. doi: 10.1097/MEJ.0b013e32835c53b3.
  18. 18.
    Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother. 2011;45(5):649–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Rovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoki R. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006;28(4):362–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42(11):1703–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Tang JF, Chen PL, Tang EJ, May TA, Stiver SI. Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury. Neurocrit Care. 2011;15(1):175–81.PubMedCrossRefGoogle Scholar
  22. 22.
    DeMuro JP, Botros DG, Wirkowski E, Hanna AF. Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series. J Anesth. 2012;26(4):601–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Muzyk AJ, Revollo JY, Rivelli SK. The use of dexmedetomidine in alcohol withdrawal. J Neuropsychiatry Clin Neurosci. 2012;24(3):E45–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Jaatinen P, Riihioja P, Haapalinna A, Heinonen E, Kiianmaa K, Hervonen A. Prevention of ethanol-induced sympathetic overactivity and degeneration by dexmedetomidine. Alcohol. 1995;12(5):439–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Riihioja P, Jaatinen P, Oksanen H, Haapalinna A, Heinonen E, Hervonen A. Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Alcohol Clin Exp Res. 1997;21(5):804–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Riihioja P, Jaatinen P, Oksanen H, Haapalinna A, Heinonen E, Hervonen A. Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat. Alcohol. 1997;14(6):537–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Precedex [package insert]. Lake Forest (IL): Hospira, Inc., 2010.Google Scholar
  28. 28.
    Szumita PM, Baroletti SA, Anger KE, Wechsler ME. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm. 2007;16:37–44.CrossRefGoogle Scholar
  29. 29.
    Bamgbade OA. Dexmedetomidine for peri-operative sedation and analgesia in alcohol addiction. Anaesthesia. 2006;61(3):299–300.PubMedCrossRefGoogle Scholar
  30. 30.
    Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98(2):575–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Heinz A, Schmidt K, Baum SS, et al. Influence of dopaminergic transmission on severity of withdrawal syndrome in alcoholism. J Stud Alcohol. 1996;57:471–4.PubMedGoogle Scholar
  32. 32.
    Krystal JH, Tabakoff B. Ethanol abuse, dependence and withdrawal: neurobiology and clinical implications. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: 5th generation of progress. New York: Lippincott Williams and Wilkins; 2002. p. 1425–43.Google Scholar
  33. 33.
    Myrick H, Anton RF. Treatment of alcohol withdrawal. Alcohol Health Res World. 1998;22:38–43.PubMedGoogle Scholar
  34. 34.
    Hawley RJ, Nemeroff CB, Bissette G, et al. Neurochemical correlates of sympathetic activation during severe alcohol withdrawal. Alcohol Clin Exp Res. 1994;18:1312–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Walker BM, Rasmussen DD, Raskind MA, Koob GF. Alpha-1 noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol. 2008;42:91–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, et al. Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. Alcohol. 2003;38:224–31.Google Scholar
  37. 37.
    Riihioja P, Jaatinen P, Haapalinna A, Kiianmaa K, Hervonen A. Effects of dexmedetomidine on rat locus coeruleus and ethanol withdrawal symptoms during intermittent ethanol exposure. Alcohol Clin Exp Res. 1999;23(3):432–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Hoy S, Keating G. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481–501.PubMedCrossRefGoogle Scholar
  39. 39.
    Gerlach A, Murphy C, Dasta J. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43:2064–74.PubMedCrossRefGoogle Scholar
  40. 40.
    Johnson MT, Yamanaka TT, Fraidenburg DR, Kane SP. Benzodiazepine misadventure in acute alcohol withdrawal: the transition from delirium tremens to ICU delirium. J Anesth. 2013;27(1):135–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Bayard M, Mcintyre J, Hill K, Woodside J. Alcohol withdrawal syndrome. Am Fam Physician. 2004;69(6):1443–50.PubMedGoogle Scholar
  42. 42.
    Gerlach AT, Dasta JF, Steinberg S, Martin LC, Cook CH. A new dosing protocol reduces dexmedetomidine hypotension in critically ill surgical patients. J Crit Care. 2009;24(4):568–74.PubMedCrossRefGoogle Scholar
  43. 43.
    Maclaren R, Krisl JC, Cochrane RE, Mueller SW. A case-based approach to the practical application of dexmedetomidine in critically ill adults. Pharmacotherapy. 2013;33(2):165–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30:2188–96.PubMedCrossRefGoogle Scholar
  45. 45.
    Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009;35:282–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Reade MC, O’Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs haloperidol in delirious, agitated, intubated patients: a randomized open-label trial. Critical Care. 2009;13(3):R75.PubMedCrossRefGoogle Scholar
  47. 47.
    Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit care. 2010;12(3):356–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Andrew J. Muzyk
    • 1
    • 2
    Email author
  • Suzanne Kerns
    • 2
  • Scott Brudney
    • 3
  • Jane P. Gagliardi
    • 2
    • 4
  1. 1.Department of Pharmacy PracticeCampbell University School of Pharmacy and Health SciencesBuies CreekUSA
  2. 2.Department of Psychiatry and Behavioral SciencesDuke UniversityDurhamUSA
  3. 3.Durham VAMC Surgical Intensive Care UnitDurhamUSA
  4. 4.Department of MedicineDuke UniversityDurhamUSA

Personalised recommendations